Related Experiment Video
Updated: Jun 25, 2026
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders
Sho-ichi Yamagishi1, Takanori Matsui, Kazuo Nakamura
1Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
Insights
Pigment epithelium-derived factor (PEDF) shows promise as a novel therapeutic strategy for preventing cardiovascular disease (CVD). Its antioxidant and anti-inflammatory properties may combat atherosclerosis in high-risk patients.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Biochemistry
Background:
- Cardiovascular disease (CVD) remains a primary cause of mortality despite therapeutic advances.
- Atherosclerosis poses significant risks, necessitating novel preventive strategies.
- Pigment epithelium-derived factor (PEDF) exhibits antioxidant and anti-inflammatory properties.
Purpose of the Study:
- To explore the pathophysiological role of PEDF in atherosclerosis.
- To evaluate PEDF as a potential therapeutic agent for CVD prevention.
- To discuss PEDF kinetics and regulation in human cardiometabolic disorders.
Main Methods:
- Review of existing literature on PEDF's role in vascular cells, leukocytes, and platelets.
- Analysis of PEDF's effects on neointimal hyperplasia and arterial thrombosis models.
- Discussion of PEDF kinetics and regulation in human cardiometabolic disorders.
Main Results:
- PEDF demonstrates antioxidant and anti-inflammatory effects relevant to vascular health.
- PEDF suppresses neointimal hyperplasia and arterial thrombosis.
- These findings suggest PEDF substitution as a potential therapeutic strategy.
Conclusions:
- PEDF holds significant therapeutic potential for preventing atherosclerosis and CVD.
- Further investigation into PEDF's role and regulation in human cardiometabolic disorders is warranted.
- PEDF substitution may offer a novel approach for managing high-risk atherosclerosis patients.
Abstract:
Although remarkable therapeutic advances in the treatment of cardiometabolic disorders have been made with current therapeutic options, cardiovascular disease (CVD) is still a leading cause of mortality and morbidity in the Western world. Therefore, to develop a novel therapeutic strategy is needed for the prevention of cardiovascular disease (CVD) in high-risk patients for atherosclerosis. Recently, we, along with others, have shown that pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, exerts anti-oxidative and anti-inflammatory properties in vascular wall cells, leukocytes and platelets. In addition, PEDF not only suppresses neointimal hyperplasia after balloon angioplasty, but also blocks occlusive thrombus formation in a rat arterial thrombosis model. These observations suggest that substitution of PEDF may be a novel therapeutic strategy for atherosclerosis. This article summarizes the pathophysiological role of PEDF in atherosclerosis and its potential therapeutic implication in this devastating disorder. We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans.
More Related Videos
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
10:00Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells
Published on: December 11, 2020